Financial Snapshot

Revenue
$5.849M
TTM
Gross Margin
Net Earnings
-$245.7M
TTM
Current Assets
$305.4M
Q2 2023
Current Liabilities
$52.47M
Q2 2023
Current Ratio
582.06%
Q2 2023
Total Assets
$488.8M
Q2 2023
Total Liabilities
$131.8M
Q2 2023
Book Value
$357.0M
Q2 2023
Cash
$127.1M
Q2 2023
P/E
-11.81
Aug 18, 2023 EST
Free Cash Flow
-$175.9M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $2.9002 Billion

About CHINOOK THERAPEUTICS, INC.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 214 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.

Industry: Pharmaceutical Preparations Peers: Akero Therapeutics, Inc. VERACYTE, INC. CATALYST PHARMACEUTICALS, INC. Deciphera Pharmaceuticals, Inc. FIBROGEN INC Kymera Therapeutics, Inc. RHYTHM PHARMACEUTICALS, INC. SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals, Inc.